Durvalumab consolidation therapy in patients with stage III non-small cell lung cancer after concurrent chemoradiation: a China-based cost-effectiveness analysis

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 Feb;4(3):209–249.
   Google Scholar
• Morgensztern D, Ng SH, Gao F, et al. Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey. J Thorac Oncol. 2010 Jan;5(1):29–33.
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018 Dec 13;379(24):2342–2350.
   PubMed Web of Science ®Google Scholar
• Gray JE, Villegas A, Daniel D, et al. Three-year overall survival with durvalumab after chemoradiotherapy in stage III NSCLC-update from PACIFIC. J Thorac Oncol. 2020 Feb;15(2):288–293.
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Spira A, Raben D, et al. Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial. Ann Oncol. 2020 Jun;31(6):798–806.
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017 Nov 16;377(20):1919–1929.
   PubMed Web of Science ®Google Scholar
• Faivre-Finn C, Vicente D, Kurata T, et al. Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC-an update from the PACIFIC trial. J Thorac Oncol. 2021 May;16(5):860–867.
   PubMed Web of Science ®Google Scholar
• FDA. FDA approves durvalumab after chemoradiation for unre-sectable stage III NSCLC 2018 [cited 2018 Feb 20]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-durvalumab-after-chemoradiation-unresectable-stage-iii-nsclc
   Google Scholar
• Criss SD, Mooradian MJ, Sheehan DF, et al. Cost-effectiveness and budgetary consequence analysis of durvalumab consolidation therapy vs no consolidation therapy after chemoradiotherapy in stage III non–small cell lung cancer in the context of the US health care system. JAMA Oncol. 2019;5(3):358–365.
   PubMed Web of Science ®Google Scholar
• Han J, Tian K, Yang J, et al. Durvalumab vs placebo consolidation therapy after chemoradiotherapy in stage III non-small-cell lung cancer: an updated PACIFIC trial-based cost-effectiveness analysis. Lung Cancer. 2020 Aug;146:42–49.
   PubMed Web of Science ®Google Scholar
• Panje CM, Lupatsch JE, Barbier M, et al. A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC responding to definitive radiochemotherapy in Switzerland. Ann Oncol. 2020 Apr;31(4):501–506.
   PubMed Web of Science ®Google Scholar
• Mehra R, Yong C, Seal B, et al. Cost-effectiveness of durvalumab after chemoradiotherapy in unresectable Stage III NSCLC: a US healthcare perspective. J Natl Compr Canc Netw. 2021 Feb;19(2):153–162.
   PubMed Web of Science ®Google Scholar
• Armeni P, Borsoi L, Fornaro G, et al. Cost-effectiveness and Net Monetary Benefit of Durvalumab Consolidation Therapy Versus No Consolidation Therapy After Chemoradiotherapy in Stage III Non–small Cell Lung Cancer in the Italian National Health Service. Clinical Therapeutics. 2020;42(5):830–847.
   PubMed Web of Science ®Google Scholar
• Chinese Medical Association.Oncology Society of Chinese Medical Association, Chinese Medical Association Publishing House. Chinese Medical Association guidelines for clinical diagnosis and treatment of lung cancer (2019 edition).Chinese Journal of Oncology.2020;2020 Apr 23 42(4):257–287.
   Google Scholar
• Caicun Z, Jie W, Hong B, et al. Chinese experts consensus on immune checkpoint inhibitors for non-small cell lung cancer (2019 version). Chinese Journal of Lung Cancer. 2020;23. 2.
   Google Scholar
• Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018 May 31;378(22):2078–2092.
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018 Nov 22;379(21):2040–2051.
   PubMed Web of Science ®Google Scholar
• Robinson LA, Hammitt JK, Chang AY, et al. Understanding and improving the one and three times GDP per capita cost-effectiveness thresholds. Health Policy Plan. 2017 Feb;32(1):141–145.
   PubMed Web of Science ®Google Scholar
• National Bureau of Statistics of China. Statistical communiqué of the People’s Republic of China on the 2020 national economic and social development 2020, February 28 [cited 2021 Mar 3th]. Available from: http://www.stats.gov.cn/english/PressRelease/202102/t20210228_1814177.html
   Google Scholar
• Hoyle MW, Henley W. Improved curve fits to summary survival data: application to economic evaluation of health technologies. BMC Med Res Methodol. 2011;11(1):139.
   PubMed Web of Science ®Google Scholar
• Ting Z, Aixia M. The survival analysis applied in calculation of markov model transition probability in pharmaceutical evaluation. Chinese Journal of Evidence-Based Medicine. 2018;10:1129–1133.
   Google Scholar
• National Bureau of Statistics of China. China Population and Employment Statistics Yearbook 2019 2020 [cited 2022 Dec 30]. Available from: https://www.yearbookchina.com/navipage-n3020021405000178.html
   Google Scholar
• MENET. Leading platform for pharmaceutical and health information 2020 [updated 2020 Nov 25th]. Available from: https://shuju.menet.com.cn/NEWVIPZone/KKSearch/kkSearchIndex.jsp
   Google Scholar
• The Organization for Economic Co-operation and Development (OECD). Exchange rates 2020 [2021 Jan 31]. Available from: https://data.oecd.org/conversion/exchange-rates.htm
   Google Scholar
• Lu S, Yu Y, Fu S, et al. Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China. 2018;13(10):e0205827.
   Google Scholar
• G-m Z, Y-j X, X-x G, et al. Reference intervals of total bilirubin, ALT, AST, and creatinine in healthy elderly Chinese. Medical science monitor: international medical journal of experimental and clinical research. 2014; 20: 1778.
   PubMed Web of Science ®Google Scholar
• China National Healthcare Security Administration. China healthcare security diagnosis related groups (CHS-DRG) Beijing: china National Healthcare Security Administration; 2019 [cited 2020 Apr 7th]. Available from: http://www.nhsa.gov.cn/art/2019/10/24/art_37_1878.html
   Google Scholar
• Wu B, Dong B, Xu Y, et al. Economic evaluation of first-line treatments for metastatic renal cell carcinoma: a cost-effectiveness analysis in a health resource–limited setting. PloS one. 2012;7(3):e32530.
   PubMed Web of Science ®Google Scholar
• You R, Liu J, Wu DB-C, et al. Cost-effectiveness analysis of EGFR mutation testing and Afatinib versus gemcitabine-cisplatin as first-line therapy for advanced non-small-cell lung cancer in China. J Cancer Management Research. 2019; 11: 10239.
   PubMed Web of Science ®Google Scholar
• Wan N, Zhang T, Hua S, et al. Cost-effectiveness analysis of pembrolizumab plus chemotherapy with PD-L1 test for the first‐line treatment of NSCLC. Cancer Medicine. 2020;9(5):1683–1693.
   PubMed Web of Science ®Google Scholar
• Guan H, Liu G, Xie F, et al. Cost-effectiveness of osimertinib as a second-line treatment in patients with EGFR-mutated advanced non–small cell lung cancer in China. Clinical Therapeutics. 2019;41(11):2308–2320. e11.
   PubMed Web of Science ®Google Scholar
• Cao H, Wang J, Shi YJCGP. Survey of the advanced cancer patients’ medical costs in registered hospice care agencies in five provinces and municipalities. Chin Gen Pract. 2010;13:3544–3546.
   Google Scholar
• Shen Y, Wu B, Wang X, et al. Health state utilities in patients with advanced non-small-cell lung cancer in China. Journal of Comparative Effectiveness Research. 2018;7(5):443–452.
   PubMed Web of Science ®Google Scholar
• Nafees B, Lloyd AJ, Dewilde S, et al. Health state utilities in non–small cell lung cancer: an international study. Asia‐pacific Journal of Clinical Oncology. 2017;13(5):e195–e203.
   PubMed Web of Science ®Google Scholar
• Wheeler SB, Rotter JS, Baggett CD, et al. Cost-effectiveness of endocrine therapy versus radiotherapy versus combined endocrine and radiotherapy for older women with early-stage breast cancer. J Geriatr Oncol. 2021;12(5):741–748.
   PubMed Web of Science ®Google Scholar
• Zhang X, Wang J, Shi J, et al. Cost-effectiveness of atezolizumab plus bevacizumab vs sorafenib for patients with unresectable or metastatic hepatocellular carcinoma. JAMA Network Open. 2021;4(4):e214846.
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. New England Journal of Medicine. 2017;377(20):1919–1929.
   PubMed Web of Science ®Google Scholar
• Yang Z, Zhu Y, Xiang G, et al. First-line atezolizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: a cost-effectiveness analysis from China. Expert Rev Pharmacoecon Outcomes Res. 2021;19:1–7.
   Google Scholar
• Liu Q, Luo X, Peng L, et al. Nivolumab versus docetaxel for previously treated advanced non-small cell lung cancer in China: a cost-effectiveness analysis. Clin Drug Investig. 2020 Feb;40(2):129–137.
   PubMed Web of Science ®Google Scholar
• Liao W, Huang J, Hutton D, et al. Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China. J Med Econ. 2019 Apr;22(4):344–349.
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O. Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: a meta-analysis. Crit Rev Oncol Hematol. 2016;101:75–85. 2016 may 01/.
   PubMed Web of Science ®Google Scholar
• Aguiar JPN, Santoro IL, Tadokoro H, et al. The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis. Immunotherapy. 2016;8(4):479–488.
   PubMed Web of Science ®Google Scholar
• Mayoux M, Roller A, Pulko V, et al. Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy. Sci Transl Med. 2020 Mar 11;12(534):534.
   Web of Science ®Google Scholar
• Aguiar PN Jr., Perry LA, Penny-Dimri J, et al. The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC. Ann Oncol. 2017 Sep 1;28(9):2256–2263.
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Vicente D, Tafreshi A, et al. A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of KEYNOTE-407. J Thorac Oncol. 2020 Oct;15(10):1657–1669.
   PubMed Web of Science ®Google Scholar
• Gadgeel S, Rodriguez-Abreu D, Speranza G, et al. Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol. 2020 May 10;38(14):1505–1517.
   PubMed Web of Science ®Google Scholar
• Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019 May 4;393(10183):1819–1830.
   PubMed Web of Science ®Google Scholar
• Luo Z, Gyawali B, Han S, et al. Can locally developed me-too drugs aid price negotiation? An example of cancer therapies from China. Semin Oncol. 2021. https://doi.org/10.1053/j.seminoncol.2021.03.001.
   Google Scholar
• Islam KMM, Jiang X, Anggondowati T, et al. Comorbidity and survival in lung cancer patients. Cancer Epidemiol Prev Biomarkers. 2015;24(7):1079–1085.
   PubMed Web of Science ®Google Scholar